National Taiwan University Hospital (NTUH) has officially launched PANCREASaver, the world’s first AI-powered diagnostic system designed to detect early-stage pancreatic cancer. Developed in partnership with the Institute of Applied Mathematical Sciences at National Taiwan University, the system marks a milestone in precision medicine and artificial intelligence integration in clinical care.
Often called the “king of cancers,” pancreatic cancer is notorious for its silent onset, fast progression, and poor prognosis. It’s projected to become the second leading cause of cancer-related deaths in the United States by 2030, and has already climbed to the seventh leading cause in Taiwan. The disease’s five-year survival rate hovers at just 10%—a grim statistic that dramatically improves to nearly 80% if tumors smaller than 2 centimeters are caught early.
Yet these early-stage tumors are notoriously difficult to detect on conventional CT scans. Around 40% of such lesions are missed, making diagnosis heavily dependent on the experience of radiologists. PANCREASaver steps in to bridge this gap.
Leveraging deep learning algorithms and trained on multi-image datasets, PANCREASaver automatically scans CT images, delineates the pancreas, and flags suspicious lesions—all integrated directly into NTUH’s picture archiving and communication system (PACS). Clinical trials in Taiwan show the system reaches an 80% sensitivity rate for detecting tumors under 2 cm and over 90% overall diagnostic accuracy.
“PANCREASaver significantly boosts our ability to detect pancreatic cancer at a treatable stage,” the University stated in a press statement. “It supports radiologists, rather than replacing them, allowing for faster and more confident diagnoses.”
In one notable case, a 67-year-old woman arrived at NTUH with symptoms of jaundice and itching. Her initial CT scan showed bile duct dilation, but no visible tumor. PANCREASaver flagged a subtle anomaly, prompting further evaluation via endoscopic ultrasound. A small tumor in the pancreatic head was confirmed, allowing for timely surgical intervention—and potentially saving her life.
PANCREASaver has received regulatory approval from the Taiwan Food and Drug Administration (TFDA) and has been granted the U.S. FDA Breakthrough Device Designation. It also holds eight patents—four in Taiwan and four in the United States—and has earned accolades such as the RSNA Margulis Award, National Innovation Award, and SNQ National Quality Certification. Research supporting the system’s efficacy has been featured in top-tier journals, including The Lancet Digital Health and Radiology.
Currently offered as a self-pay service through NTUH’s Department of Medical Imaging, PANCREASaver is also integrated into multidisciplinary teams spanning gastroenterology, oncology, and surgery. The developers plan to expand the system’s capabilities to cover conditions like pancreatitis and pancreatic cystic lesions, while incorporating multi-modal imaging and clinical data for broader precision medicine applications.
As AI continues to evolve in healthcare, PANCREASaver stands as a compelling example of how technology and medicine can come together to fight disease with unprecedented precision and hope.
